Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors

被引：0
|
作者：
Siu, Lillian L.
Gil-Martin, Marta
Cho, Byoung Chul
Perets, Ruth
Hilton, John
Geva, Ravit
Lugowska, Iwona
Gutierrez, Martin
Bonomi, Marcelo
Dziadziuszko, Rafal
Rasco, Drew
Ben-Ami, Eytan
Rodriguez, Cristina P.
Siddiqi, Shabana
Myer, Nicole
Suttner, Leah
Wilson, Douglas
Akala, Ombololaji O.
de Miguel, Maria
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT104
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors: Dose escalation study
    Taylor, Matthew H.
    Patel, Manish R.
    Powderly, John D.
    Woodard, Paul
    Chung, Luke
    Tian, Hongyu
    Hong, Xiang
    Hong, Kyu
    Valencia, Donna
    Huang, Tao
    Schebye, Xiao Min
    Liao, Charlene
    Naing, Aung
    CANCER RESEARCH, 2023, 83 (08)
  • [22] A PHASE 1 STUDY OF NECITUMUMAB (ANTI-EGFR MONOCLONAL ANTIBODY) IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Tamura, Yosuke
    Tanabe, Yuko
    Honda, Kazunori
    Asahina, Hajime
    Enatu, Sotaro
    Kurek, Raffael
    Yamada, Yasuhide
    Tamura, Tomohide
    ANNALS OF ONCOLOGY, 2014, 25
  • [23] Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors
    LoRusso, Patricia M.
    Gounder, Mrinal
    Jalal, Shadia I.
    Andre, Valerie
    Kambhampati, Siva Rama Prasad
    Loizos, Nick
    Hall, Jennifer
    Holzer, Timothy R.
    Nasir, Aejaz
    Cosaert, Jan
    Kauh, John
    Chiorean, E. Gabriela
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (04) : 442 - 450
  • [24] Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors
    Patricia M. LoRusso
    Mrinal Gounder
    Shadia I. Jalal
    Valérie André
    Siva Rama Prasad Kambhampati
    Nick Loizos
    Jennifer Hall
    Timothy R. Holzer
    Aejaz Nasir
    Jan Cosaert
    John Kauh
    E. Gabriela Chiorean
    Investigational New Drugs, 2017, 35 : 442 - 450
  • [25] Initial results from the Phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors
    Schram, Alison
    Spreafico, Anna
    Oliva, Marc
    Brana, Irene
    Garralda, Elena
    Lakhani, Nehal
    Von Hoff, Daniel
    Borazanci, Erkut
    Pandya, Naimish
    Hoffman, Kimberly
    Hallett, Robin
    Giblin, Patricia
    Anido, Judit
    Kelly, Adrianne
    Wasserman, Robert
    Seoane, Joan
    Siu, Lillian
    Hyman, David M.
    Tabernero, Josep
    CANCER RESEARCH, 2019, 79 (13)
  • [26] A phase 1 study of BAT8007, an anti-nectin-4 monoclonal antibody-exatecan conjugate, in patients with advanced solid tumors.
    Jiang, Lijuan
    Song, Zhengbo
    Gong, Yi
    Jin, Jianan
    Ding, Yao
    Tang, Long
    Deng, Xia
    Li, Xiangdong
    Li, Su
    Cheng, Xiangdong
    Zhou, Fangjian
    Zhou, Xiaoyan
    Fu, Ziyi
    Yu, Jin-Chen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors
    Geva, Ravit
    Voskoboynik, Mark
    Dobrenkov, Konstantin
    Mayawala, Kapil
    Gwo, Jennifer
    Wnek, Richard
    Chartash, Elliot
    Long, Georgina V.
    CANCER, 2020, 126 (22) : 4926 - 4935
  • [28] A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors (NCT05054348).
    Powderly, John
    Patel, Manish
    Woodard, Paul
    Chung, Luke
    Tian, Hongyu
    Wieland, Elizabeth
    Hong, Kyu
    Costa, Maria Jose
    Liao, X. Charlene
    Taylor, Matthew
    CANCER RESEARCH, 2022, 82 (12)
  • [29] A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
    Atzori, Francesco
    Tabernero, Josep
    Cervantes, Andres
    Prudkin, Ludmila
    Andreu, Jordi
    Rodriguez-Braun, Edith
    Domingo, Amparo
    Guijarro, Jorge
    Gamez, Cristina
    Rodon, Jordi
    Di Cosimo, Serena
    Brown, Holly
    Clark, Jason
    Hardwick, James S.
    Beckman, Robert A.
    Hanley, William D.
    Hsu, Karl
    Calvo, Emiliano
    Rosello, Susana
    Langdon, Ronald B.
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2011, 17 (19) : 6304 - 6312
  • [30] A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
    Garralda, Elena
    Sukari, Ammar
    Lakhani, Nehal J.
    Patnaik, Amita
    Lou, Yanyan
    Im, Seock-Ah
    Golan, Talia
    Geva, Ravit
    Wermke, Martin
    De Miguel, Maria
    Palcza, John
    Jha, Sujata
    Chaney, Marya F.
    Healy, Jane Anne
    Falchook, Gerald Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345